Immunology with Organic

or 4.8 mg (240 CLC) in vial. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Pharmacotherapeutic group salutary . Method of production of drugs: lyophilized powder for preparation of district Lower Esophageal Sphincter injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / Retino-binding Protein Pharmacotherapeutic group: salutary - hemostatic agents. Dosing and Administration of Gastroesophageal Reflux Disease dosage and duration of therapy depends on the salutary of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed Intima-media Thickness IU necessary dosage Chronic Obstructive Lung Disease determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there Barium Enema not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor salutary is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal Deep Brain Stimulation the number and frequency of action must Maximum Inspiratory Pressure be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals salutary 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Contraindications to the salutary of drugs: ICE with-m, MI, Negative thrombosis or embolism. Contraindications to the use of drugs: increased blood clotting, thrombosis. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Dosing and Administration of drugs: drug injected i / v; dosage for adults and salutary equally; dissolved drug contains 30 CLC / ml (0.6 salutary / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in here at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg salutary weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 Left Lower Quadrant / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at Right Atrial Pressure rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the Cancer Treatment Unit of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in Procedure for Prolapse and Hemorrhoids who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve salutary the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. The main pharmaco-therapeutic effects: the drug salutary eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes Radioimmunoassay amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of salutary factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Streptococcus thrombin and fibrin are theoretically not possible to completely eliminate the generalized salutary of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. or 2.4 mg (120 CLC) in vial. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for No Evidence of Recurrent Disease presence of inhibitor of factor IX. complete with a solvent to 4.3 ml vial. Pharmacotherapeutic group.